Taken together, clinical and especially biological prognostic factors like MIB-1 could help identify patients with a high risk of tumor relapse who might benefit from early and intensified adjuvant radiotherapy as well as from dose escalation of macroscopic tumor tissue. This evidence concerns the gene MIB1 and neoplasm.